JMP puts NeoPharm at strong buy

NeoPharm, Inc. was given a strong buy rating with a $19 price target by JMP Securities analyst Charles C. Duncan. NeoPharm's reported fourth-quarter 2005 results that were roughly in line with the analyst's consensus expectations. Jefferies does not project the interim efficacy analysis from the Precise trial, triggered by 160 deaths, will hit the high level of statistical significance required to end the trial early. The timing of the analysis (expected in mid-2006) will remain the focal point for investors in the near term. Shares of the Lake Forest, Ill., pharmaceutical company were up 33 cents, or 3.26%, at $10.45 on volume of 431,072 shares versus the three-month running average of 844,983 shares. (Nasdaq: NEOL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.